Skip to content

Evaluation of liposomal Bupivacaine for Thoracic Paravertebral Block for Postoperative Analgesia and Safety in Thoracic Surgery Patients

Evaluation of liposomal Bupivacaine for Thoracic Paravertebral Block for Postoperative Analgesia and Safety in Thoracic Surgery Patients: A Prospective, Randomized Exploratory Study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101693
Enrollment
Unknown
Registered
2025-04-28
Start date
2025-05-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Liposomal bupivacaine ropivacaine mixed group:Liposomal bupivacaine 20 ml mixed with 5 ml of 0.375% ropivacaine hydrochloride injection was used for thoracic paravertebral nerve block.
Ropivacaine group:The ropivacaine group was medicated with 0.375% ropivacaine hydrochloride 25 ml for thoracic paravertebral nerve blocks.
Liposomal bupivacaine group:In the liposomal bupivacaine group, liposomal bupivacaine 266 mg 20 ml mixed with 5 ml of saline was used for thoracic paravertebral nerve block.

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-65, ASA I-III; 2.Patient with proposed single-port thoracoscopy-assisted partial resection/ segment resection/lobectomy under general anesthesia; 3.Consent for regional nerve block and postoperative intravenous self-controlled analgesia.

Exclusion criteria

Exclusion criteria: 1. Converted to open thoracic surgery; 2. Contraindicated to deep nerve block; 3. Preoperative severe hepatic or renal insufficiency; 4. Chronic opioid dependence and chronic users of various types of pain medication; 5. Alcohol and/or drug abuse; 6. Known hypersensitivity to local anesthetics; 7. Hard to communicate due to severe dementia, language impairment, or end-stage disease; 8. Recent antipsychiatric medication use; 9. Expected to be admiitted to ICU; 10. With the situations which preclude the participation in the opinion of the investigator or the attending physician;

Design outcomes

Primary

MeasureTime frame
Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Score at 0-72 hours postoperatively;

Secondary

MeasureTime frame
Postoperative 2-72h pain intensity ratings and indicators of opioid consumption;Block quality was evaluated: dermatomal block range, time to peak block, total duration of nerve block manipulation, and nerve block-related adverse events;;Bupivacaine concentration in blood;Opioid use in the 72h postoperative period;

Countries

China

Contacts

Public ContactSong Linlin

Peking University First Hospital

1131_1131@163.com+86 10 8357 5138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026